Company Overview

Alterity Therapeutics Limited is a clinical-stage biotechnology company focused on developing disease-modifying therapies for neurodegenerative disorders. The company operates within the biopharmaceutical and neurology sectors, with a primary emphasis on conditions characterized by abnormal protein aggregation and neurodegeneration. Alterity’s core scientific focus is on Parkinsonian disorders, particularly Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease with no approved disease-modifying treatments.

The company’s principal product candidate is ATH434, an orally administered small molecule designed to restore normal iron balance in the brain, thereby reducing α-synuclein pathology and neuronal damage. Alterity’s strategic positioning centers on targeting a well-defined, underserved patient population with high unmet medical need. The company was originally founded in Australia and has evolved from earlier research programs into a focused clinical-stage organization following restructuring and asset prioritization around ATH434.

Business Operations

Alterity operates primarily as a research and development organization, generating value through the advancement of its drug candidates through clinical trials rather than through product sales. Its operations are organized around a single core business segment: neurology drug development, with internal capabilities spanning preclinical research, clinical trial management, regulatory strategy, and intellectual property development. Revenue generation to date has consisted mainly of research grants, government incentives, and capital raised through equity markets rather than commercial product revenue.

Clinical development activities are conducted through a combination of internal management and outsourced contract research organizations, enabling global trial execution while maintaining a lean operating structure. Alterity controls a portfolio of patents related to ATH434 and its underlying metal-protein interaction technology. The company has historically engaged in collaborations with academic institutions and research organizations to support translational research and clinical validation.

Strategic Position & Investments

Alterity’s strategic direction is centered on advancing ATH434 through mid- to late-stage clinical development for MSA, while also evaluating its potential applicability in related neurodegenerative diseases such as Parkinson’s disease. Growth initiatives focus on clinical milestone achievement, regulatory engagement, and the potential for strategic partnerships or licensing transactions to support late-stage development and commercialization.

The company has periodically strengthened its financial position through capital raises and non-dilutive funding, including government-backed research grants. Alterity has not reported material acquisitions of other operating companies in recent years, instead prioritizing internal development and portfolio consolidation. Emerging areas of interest include broader applications of metal homeostasis modulation in neurodegenerative disorders, though public disclosures indicate ATH434 remains the dominant investment focus.

Geographic Footprint

Alterity Therapeutics is headquartered in Australia, with additional corporate and operational presence in the United States, reflecting its dual listing structure and focus on global clinical development. Clinical trials and research collaborations have involved sites across North America, Europe, and Australia, enabling access to specialized patient populations and regulatory pathways in multiple jurisdictions.

The company’s international footprint is primarily research- and trial-driven rather than commercial, with no marketed products to date. Its global orientation is designed to support eventual regulatory approvals in major pharmaceutical markets, including the United States and Europe, should clinical outcomes support commercialization.

Leadership & Governance

Alterity is led by an executive team with experience in biotechnology, neuroscience, and drug development, overseen by a board of directors with expertise in life sciences, finance, and corporate governance. The leadership emphasizes disciplined capital allocation, scientific rigor, and a targeted approach to addressing high unmet medical needs in neurodegenerative disease.

Key executives include:

• David Stamler – President and Chief Executive Officer
• Gavin Cumming – Chief Financial Officer
• Ursula Schmitz – Chief Operating Officer
• David Hung – Non-Executive Chairman

The company’s governance framework reflects public company standards across Australian and U.S. markets, with strategic oversight focused on advancing clinical assets, managing development risk, and maximizing long-term shareholder value through scientific and regulatory execution.